Rudi Pauwels
Directeur Général chez Biocartis SA
Profil
Rudi Pauwels is the founder of Biocartis Group NV (founded in 2007), Galapagos NV (founded in 1999), Virco Group NV (founded in 1995), and Galapagos Genomics NV (founded in 1999).
He held the title of Non-Executive Director at Biocartis Group NV from 2015 to 2018, Non-Executive Director at Galapagos NV from 2009 to 2010, and Chairman & Chief Scientific Officer at Virco Group NV from 1995 to 2002.
He was also the Chairman of Galapagos Genomics NV in 2002.
Dr. Pauwels is also the founder of Tibotec Virco NV.
Dr. Pauwels currently holds the position of Executive Chairman & Chief Executive Officer at Biocartis SA (since 2013).
He is also the Chairman of Benaruca SA, Executive Chairman & Partner at ANeuroTech BV, Director at Valetusan Ltd., Director at Cambenes SA, Director at Riverwells Investments SA, Director at Calimontes SL, Director at Caruso Inversiones SL, and Member of the Investment Committee at Smile Invest Management Co. NV.
Dr. Pauwels previously held the position of Chairman at RespiVert Ltd.
He was an Independent Director at MDxHealth SA from 2013 to 2015.
He also served as a Director at MyCartis NV.
Additionally, he was a Venture Partner at Advent Venture Partners LLP from 2007 to 2011.
Dr. Pauwels obtained a doctorate degree from Katholieke Universiteit Leuven.
Postes actifs de Rudi Pauwels
| Sociétés | Poste | Début |
|---|---|---|
Biocartis SA
 Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Directeur Général | 02/07/2007 |
Valetusan Ltd.
 Valetusan Ltd. Miscellaneous Commercial ServicesCommercial Services Valetusan Ltd. is an Irish private company located in Dublin that provides business and management consultancy services. | Directeur/Membre du Conseil | - |
| Benaruca SA | Président | - |
| Cambenes SA | Directeur/Membre du Conseil | - |
| Riverwells Investments SA | Directeur/Membre du Conseil | - |
| Calimontes SL | Directeur/Membre du Conseil | - |
| Caruso Inversiones SL | Directeur/Membre du Conseil | - |
Smile Invest Management Co. NV
 Smile Invest Management Co. NV Investment ManagersFinance Smile Invest Management Co. NV (Smile Invest) is a private equity firm founded in 2017 by Urbain Vandeurzen. The firm is headquartered in Linden. | Private Equity Investor | - |
ANeuroTech
 ANeuroTech Miscellaneous Commercial ServicesCommercial Services ANeuroTech is a Belgian mental health company that specializes in developing innovative treatments with minimal or no side effects. ANeuroTech is located in Belgium. The private company's lead asset, ant-01, is an adjunctive anti-depression drug that has shown positive results in late-stage clinical trials. The drug is a low-dose of an existing substance, pipamperone dihydrochloride, and has an excellent safety profile. ANeuroTech plans to begin a pivotal phase iiib clinical trial of ant-01 as an adjunctive anti-depression drug for major depressive disorder (MDD) in 2023. The company was founded by CEO Dr. Erik Buntinx, an experienced clinician and key opinion leader in the field. | Président | - |
Anciens postes connus de Rudi Pauwels
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░ ░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | - |
| ░░░░░░ ░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░ | ░░░░░░░░░ | - |
| ░░░░░░░ ░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░ ░░ | ░░░░░░░░░ | - |
Formation de Rudi Pauwels
| Katholieke Universiteit Leuven | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GALAPAGOS NV | Health Technology |
| MDXHEALTH SA | Health Technology |
| BIOCARTIS GROUP NV | Health Technology |
| Entreprise privées | 15 |
|---|---|
RespiVert Ltd.
 RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Distribution Services |
Biocartis SA
Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Health Technology |
Tibotec Virco NV
 Tibotec Virco NV Miscellaneous Commercial ServicesCommercial Services Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium. | Commercial Services |
| Virco Group NV | Commercial Services |
Galapagos Genomics NV
 Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Health Technology |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Finance |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Health Technology |
Valetusan Ltd.
Valetusan Ltd. Miscellaneous Commercial ServicesCommercial Services Valetusan Ltd. is an Irish private company located in Dublin that provides business and management consultancy services. | Commercial Services |
| Benaruca SA | Miscellaneous |
| Cambenes SA | |
| Riverwells Investments SA | |
| Calimontes SL | |
| Caruso Inversiones SL | |
Smile Invest Management Co. NV
Smile Invest Management Co. NV Investment ManagersFinance Smile Invest Management Co. NV (Smile Invest) is a private equity firm founded in 2017 by Urbain Vandeurzen. The firm is headquartered in Linden. | Finance |
ANeuroTech
ANeuroTech Miscellaneous Commercial ServicesCommercial Services ANeuroTech is a Belgian mental health company that specializes in developing innovative treatments with minimal or no side effects. ANeuroTech is located in Belgium. The private company's lead asset, ant-01, is an adjunctive anti-depression drug that has shown positive results in late-stage clinical trials. The drug is a low-dose of an existing substance, pipamperone dihydrochloride, and has an excellent safety profile. ANeuroTech plans to begin a pivotal phase iiib clinical trial of ant-01 as an adjunctive anti-depression drug for major depressive disorder (MDD) in 2023. The company was founded by CEO Dr. Erik Buntinx, an experienced clinician and key opinion leader in the field. | Commercial Services |
